

NBCC

NATIONAL BREAST CANCER COALITION

grassroots advocacy in action

2002

CONGRESSIONAL
VOTING RECORD

107th CONGRESS

2002 Congressional Voting Record 107th Congress

INTRODUCTION / PREAMBLE:

The National Breast Cancer Coalition (NBCC) presents its *2002 Congressional Voting Record*. This document measures Members of Congress' support for the National Breast Cancer Coalition's (NBCC) legislative priorities in the first and second sessions of the 107th Congress (January 2001 – October 2002). NBCC believes that through passage of substantive breast cancer policy we will move closer to our goal of eradicating breast cancer. NBCC's legislative priorities were developed after a great deal of research and analysis, and with input from women and their families across the nation. This Guide reflects Congressional support for this agenda.

NBCC is a grassroots organization dedicated to ending breast cancer through the power of action and advocacy. Made up of more than 600 member organizations and tens of thousands of individual members, the National Breast Cancer Coalition publishes a Congressional Voting Record each year to remind public policy officials and their constituents that breast cancer is both a health issue and a political issue.

This Record contains information about NBCC's legislative priorities only -- it does not include *all* votes and bills related to breast cancer. The Coalition's legislative agenda stems from its three primary goals:

- (1) To increase the effectiveness of breast cancer research and the resources available to it;
- (2) To improve access for all women to high-quality health care and clinical trials; and
- (3) To expand the influence of breast cancer advocates in all aspects of the breast cancer decision-making process.

The Coalition is selective in prioritizing specific public policy goals. NBCC focuses on the initiatives that are the *most likely* to move us forward in our mission to eradicate breast cancer. NBCC's commitment to a partnership with the scientific community, policy makers and consumers assists the Coalition in making decisions about what public policy issues to support and advocate for, and which not to endorse. These decisions are sometimes unpopular, but always well informed.

NBCC also takes seriously its responsibility to help Members of Congress make informed decisions about breast cancer and to educate women and men across the country about this important public policy issue.

The National Breast Cancer Coalition recently launched a new public service campaign in the fight to eradicate breast cancer and released a national poll showing that more than fifty percent of Americans would be more likely to vote for a candidate who made finding a cure for breast cancer a top priority.

The "*Not Just Ribbons*" campaign emphasizes that symbols must be aligned with effective advocacy to win the fight against breast cancer. There is no credit given in this guide for wearing a pink ribbon, or passing an awareness resolution. While awareness about breast cancer is important, we believe that Congress must move beyond these gestures to focus on substantive breast cancer policy.

NBCC appreciates the many bipartisan Members of Congress who supported our priorities during the 107th Congress including:

- continued funding for the unique Department of Defense (DoD) Peer-Reviewed Breast Cancer Research Program (BCRP)
- passage of legislation to ensure cancer patients have access to the treatments they need

- increased co-sponsorship and strong Senate Committee report language for the Breast Cancer and Environmental Research Act
- increased co-sponsorship and congressional hearings on the Genetic Nondiscrimination in Health Insurance and Employment Act
- passage of a strong Patients' Bill of Rights in the Senate

Despite the support from many committed Members of Congress, NBCC is disappointed that at the end of the 107th Congress only one out of five of our legislative agenda remained unfinished. NBCC activists all across the country are now mobilized to ask their public officials: Why hasn't more been done in the 107th Congress to eradicate breast cancer? What, specifically, have you done to enact substantive breast cancer policy this year? NBCC grassroots activists will be enlisting friends and family across the nation to hold their Members of Congress accountable with regards to the Coalition's 2002 legislative priorities. NBCC advocates understand that the causes and cures for breast cancer will not be found only in test tubes. They must be fought for – in public policy forums, at research conferences, in drug company boardrooms, and yes, in the voting booth.

Please contact the National Breast Cancer Coalition at (202) 296-7477 or refer to NBCC's website at www.stopbreastcancer.org for additional information about our legislative agenda, and to find out how you can become more active in helping us to move forward in our mission to end this disease.

HOW TO USE THIS GUIDE:

This Voting Record measures Members of Congress' support for NBCC's legislative agenda by giving credit (✓) for either a vote (if the measure was voted on), co-sponsorship, or signing a letter.

The National Breast Cancer Coalition acknowledges that it is not always possible to accurately reflect a Member's leadership on a priority simply by a ✓ for co-sponsorship, signing a letter, or a 'yea' vote. NBCC recognizes that not all support can be documented, and that co-sponsorship is just one step of the process. At times, certain Members of Congress play a greater leadership role than others based on their position as a member of the leadership or as Chairperson of a relevant committee. It is for this reason the Coalition's Voting Record contains a textual section highlighting Members of Congress who deserve special recognition for their leadership regarding NBCC's legislative agenda. However, the Coalition's main gauge of support for NBCC's legislative priorities continues to be co-sponsorship demonstrating a first important step in working to enact a bill. NBCC believes it is important for Members of Congress to publicly take a position regarding our legislative priorities, and thus, to be given credit for or held accountable for that stance.

Summary of NBCC's Legislative Priorities for the 107th Congress (January 2001- October 2002)

**Please refer to NBCC's 2001 Interim Congressional Voting Record for a specific focus on the first session of the 107th Congress.*

Priority #1:

\$175 million appropriation, level funding, for the Department of Defense (DoD) Peer-Reviewed Breast Cancer Research Program (BCRP) for fiscal years (FY) 2002 and 2003 so that it may maintain its enormous success.

Priority #2:

Enactment of S. 913/H.R. 1624, the Access to Cancer Therapies Act. The National Breast Cancer Coalition believes that Congress should enact comprehensive prescription drug coverage for Medicare beneficiaries. While NBCC supports a broad approach to prescription drug coverage, it believes that a special provision might be necessary for coverage of oral anti-cancer drugs in light of certain historical and cost considerations that argue for continued access to cancer therapy under Medicare Part B. **This legislation would build on current Medicare policy by extending coverage to all cancer drugs, whether oral or injectable, for Medicare beneficiaries under Part B.**

Priority #3:

Enactment of S. 830/H.R. 1723, the bipartisan Breast Cancer and Environmental Research Act, which would make grants for multi-institutional, multi-disciplinary research centers to study the potential links between the environment and breast cancer. These centers would award grants based on a competitive, peer-reviewed process that involves consumer advocates.

It is generally believed that the environment plays a role in the development of breast cancer, but the extent of that role is not understood. The National Breast Cancer Coalition believes that this critical issue must be approached thoughtfully and methodically and that a national strategy for increasing knowledge in this area must be developed.

Priority #4:

Enactment of S. 318/H.R. 602, the Genetic Nondiscrimination in Health Insurance and Employment Act. This legislation, which has strong enforcement mechanisms that include a right to sue, would prohibit health insurers and employers from discriminating based on genetic information.

The Kassebaum-Kennedy Health Insurance Reform Act (1996) took an important first step by including genetic information among the factors that may not be used to deny or limit insurance coverage for members in a group health plan. Congress must now close the loopholes and provide comprehensive protection against genetic discrimination for all Americans.

Priority #5:

Patients deserve a comprehensive and enforceable patients' bill of rights that includes: coverage for routine health care costs associated with clinical trials; access to the right providers; involvement in treatment decisions that are based on good science; confidentiality of their health information; and the right to receive accurate information about their health plans. These rights must be backed by strong enforcement mechanisms that include a private right of action in state court.

Enactment of S. 1052/H.R. 2563, the Bipartisan Patient Protection Act, which reflects these important principles.

The following is an explanation of NBCC's legislative priorities that had specific legislative proposals in the 107th Congress. Congressional support for these various proposals is recorded in the chart that follows the text. Please note that this guide reflects congressional activity through the fall recess adjournment date of October 17, 2002.

Support for the Department of Defense (DoD) Peer-Reviewed Breast Cancer Research Program (BCRP):

Goal: To appropriate \$175 million dollars (level funding) for the Department of Defense Peer-Reviewed Breast Cancer Research Program (DoD BCRP) for FY 2002 and FY 2003.

What NBCC Asked

Members of

Congress

To Do: Sign on to a letter to the Chairmen of the House/Senate Defense Appropriations Subcommittees requesting an appropriation of \$175 million dollars for the DoD BCRP for FY 2002 and FY 2003.

What This Voter Guide

Records: Members receive a ✓ in the Voter Guide for signing onto the 2001 and 2002 DoD BCRP Dear Colleague letters.

Status: Both the House and Senate passed Defense Appropriations bills in the first session of the 107th Congress that included \$175 million for the DoD BCRP. The House bill included a provision that directed \$5 million of the \$175 for the BCRP be used for other purposes. NBCC strongly opposed this provision since it created a dangerous precedent that could eventually devastate the program's resources. This \$5 million earmark from the House bill (not included in the Senate passed bill) was dropped from the Conference bill. However, the total amount appropriated for the DoD BCRP was reduced by 15% to \$150 million for fiscal year 2002 in the final bill. (This was consistent with a 15% across the board cut on all funding for defense health programs for FY 02).

In the second session of the 107th Congress, the House and Senate passed Defense Appropriations bills that included \$150 million for the DoD BCRP. While we are disappointed that funding for the DoD BCRP was not restored to \$175 million, we are hopeful that next year there will be adequate resources to fully fund this broad-reaching, streamlined, and innovative breast cancer research model.

The Department of Defense Peer-Reviewed Breast Cancer Research Program (DoD BCRP) was created as a result of NBCC's 1993 "\$300 million more" campaign. NBCC launched this campaign after holding a series of research hearings at which fifteen of the nation's most prominent scientists working in the field of breast cancer testified. As a result of the hearings, the Coalition told Congress that an additional \$300 million would be needed in 1993 for breast cancer research, for a total of \$430 million.

Led by NBCC, women arrived in Washington, DC by the busload and swamped their Members of Congress with calls, faxes and telegrams through NBCC's hotline and constituent visits, demanding \$300 million more for breast cancer research.

The Coalition's requests were met. In 1993, we won more than \$400 million -- the first-ever significant increase in breast cancer funding. \$210 million of that increase came from the Defense budget to the Department of the Army to establish the DoD BCRP. Due to its outstanding success

and bipartisan support, Congress has continued to fund this program each year – bringing its total to more than \$1 billion for peer-reviewed breast cancer research since its inception

The DoD Peer-Reviewed Breast Cancer Research Program has led the way in forging new and innovative directions for breast cancer research. It has been a model that others have replicated. The program is renowned for its efficient use of resources – more than 90% of the funds go directly to research grants. A unique part of the program has been the inclusion of consumer advocates at every level – including the scientific merit review and programmatic review levels.

In addition to the inclusion of consumer advocates, and the program's efficiency, the DoD Breast Cancer Research Program is also a model for accountability in federal research programs. This is evidenced by the third DoD BCRP *Era of Hope* meeting held this past October. The 2002 meeting provided BCRP-funded investigators with the opportunity to share their results with the scientific community, policymakers, and the lay public. This year's meeting also allowed investigators from different fields to share knowledge and ideas that could lead to novel approaches to difficult research problems.

In the first and second sessions of the 107th Congress, NBCC asked Members of Congress to sign on to a letter to the House/Senate Defense Appropriations Chairmen requesting \$175 million for the DoD BCRP for FY 2002 and FY 2003. 65 Senators and over 250 Representatives signed on to this letter in support of increased funding for this program. Both the House and Senate Defense Appropriations Committees met our request (although the House bill included an earmark). However, NBCC is disappointed the amount was ultimately reduced by 15%, to \$150 million in the final Conference Report.

We could not have accomplished this goal without the particular leadership of the following Members of Congress:

Senate:

- **Senate Defense Appropriations Chairman Daniel Inouye (D-HI) and Ranking Member Ted Stevens (R-AK):** Led Senate Defense Appropriations Subcommittee in meeting NBCC's request for continued funding in FY 2002 and FY 2003 for the DoD BCRP.
- **Senators Olympia Snowe (R-ME), Tom Harkin (D-IA), Susan Collins (R-ME), Patrick Leahy (D-VT) and Arlen Specter (R-PA):** Led the "Dear Colleague" letter in the Senate, which requested that their colleagues sign on to a letter to the Senate Defense Appropriations Committee requesting \$175 million for the DoD BCRP for FY 2002 and FY 2003.
- **Note: Senator Tom Harkin (D-IA),** along with **Senator D'Amato (R-NY),** led the fight on the Senate floor in 1993 resulting in the \$210 million that started the DoD BCRP.

House:

- **House Defense Appropriations Chairman Jerry Lewis (R-CA) and Ranking Member John Murtha (D-PA):** Led House Appropriations Defense Subcommittee in meeting NBCC's request for continued funding in FY 2002 and FY 2003 for the BCRP. Also, they ultimately agreed to drop language, which would have set a dangerous precedent.
- **Representatives Nita Lowey (D-NY) and Connie Morella (R-MD):** Led the "Dear Colleague" letter in the House, which requested that their colleagues sign on to a letter to the House Defense Appropriations Subcommittee requesting \$175 million for the BCRP in FY 2002 and FY 2003.

Support for the Access to Cancer Therapies Act (S. 913/H.R. 1624)

Goal: To enact the Access to Cancer Therapies Act, S. 913/H.R. 1624, which would build on current Medicare policy by extending coverage to all cancer drugs, whether oral or injectable, for Medicare beneficiaries under Part B. The National Breast Cancer Coalition believes that Congress should enact comprehensive prescription drug coverage for Medicare beneficiaries. While NBCC supports a broad approach to prescription drug coverage, it believes that a special provision might be necessary for coverage of oral anti-cancer drugs in light of certain historical and cost considerations that argue for continued access to cancer therapy under Medicare Part B.

What NBCC Asked

Members of Congress

To Do: Sign on as co-sponsors to S. 913/H.R. 1624, the Access to Cancer Therapies Act, and work towards enacting it into law this year.

What This Voter Guide

Records: Members receive a ✓ in the Voter Guide for co-sponsoring S. 913/H.R. 1624, the Access to Cancer Therapies Act.

Status: H.R. 1624 has 327 co-sponsors in the House of Representatives, and was referred to the House Ways and Means Committee and the House Energy and Commerce Committee with no further action taken. S. 913 has 56 co-sponsors in the Senate, and was referred to the Senate Finance Committee.

The National Breast Cancer Coalition believes that Congress should enact comprehensive prescription drug coverage for Medicare beneficiaries. Such a program should cover all prescription drugs, preferably with affordable cost-sharing provisions that will enable access to drugs for all beneficiaries.

While NBCC supports a broad approach to prescription drug coverage, we appreciate that fiscal and political barriers inhibited substantial expansion of benefits in the 107th Congress. In light of this consideration, NBCC strongly supports S. 913/H.R. 1624, the Access to Cancer Therapies Act, that would extend Medicare coverage under Part B to all oral anti-cancer drugs. At this time, only 5-10% of cancer drug therapy is administered orally, but experts project that during the next decade that figure will rise to around 25%. To the extent that cancer therapy shifts from injectable to oral drugs, the financial burden will correspondingly shift from the Medicare program to beneficiaries personally. To avoid this result, Congress should extend Medicare coverage to all anti-cancer drugs.

While Medicare now covers some oral drugs that are self-administered, it does not cover oral anti-cancer drugs that do not have an injectable version. Drugs omitted from coverage include widely used hormonal agents for breast cancer like Tamoxifen, and also many innovative targeted new drugs available only in oral form that are under development and expected to be on the market this year.

Medicare policy must be updated to provide reliable access to these products for beneficiaries with cancer. If Medicare does not cover these new drugs, providers may have an incentive to use the more costly, more toxic and less convenient form of therapy just because it is covered by the program.

While the Access to Cancer Therapies Act had strong bipartisan support from more than half the members of the House and Senate, it was not ultimately enacted into law this session. While NBCC was disappointed that the bill did not become law, we are grateful to the leadership of the following Members of Congress on this important legislation:

Senate:

- **Senators Olympia Snowe (R-ME) and John “Jay” Rockefeller (D-WV):** introduced S.913, the Access to Cancer Therapies Act in the Senate.

House:

- **Representatives Deborah Pryce (R-OH), Ken Bentsen (D-TX), Sue Myrick (R-NC), and Lois Capps (D-CA):** introduced H.R. 1624 in the House of Representatives.

**Support for the Breast Cancer and Environmental Research
Act
(S. 830/H.R. 1723)**

Goal: To enact the bipartisan Breast Cancer and Environmental Research Act, which would authorize \$30 million for each of the fiscal years 2002 through 2007 to the National Institute of Environmental Health Sciences (NIEHS) to make grants for the development and operation of research centers regarding the study of the potential links between the environment and breast cancer. These centers would be multi-institutional and multi-disciplinary, and would award grants based on a competitive, peer-reviewed process that involves consumer advocates.

**What NBCC Asked
Members of
Congress**

To Do: Sign on as co-sponsors to S. 830/H.R. 1723, the bipartisan Breast Cancer and Environmental Research Act, and work towards enacting it into law this year.

**What This
Voter Guide**

Records: Members receive a ✓ in the Voter Guide for co-sponsoring S. 830/H.R. 1723.

Status: H.R. 1723 has 198 co-sponsors in the House of Representatives, and was referred to the House Commerce Committee with no further action taken. S. 830 has 43 co-sponsors in the Senate, and was referred to the Senate Committee on Health, Education, Labor and Pensions (HELP). The Senate HELP Committee had many opportunities to debate S. 830, the Breast Cancer and Environmental Research Act in the second session of the 107th Congress. However, all of the scheduled markups of the bill (of which there were more than five) were ultimately postponed or cancelled. As a result, there was never a recorded vote on S. 830, despite the support of three-quarters of the Senators on the HELP Committee. The Senate Labor Health and Human Services Appropriations Committee Report, however, did include strong language in support of the goals of this legislation.

Breast cancer is a complex disease that occurs in an environmentally complex world. It is generally believed that the environment plays some role in the development of breast cancer, but the extent of that role is not understood. NBCC believes that more research needs to be done to determine the impact of the environment on breast cancer, which has been understudied in the past. We believe that before we find the answers, we must figure out what are the right questions to be asking. It is important that a comprehensive strategy be developed in pursuit of the right questions, and the right answers, towards knowing how to prevent, treat, and ultimately cure breast cancer.

The National Breast Cancer Coalition supports passage of S. 830/H.R. 1723, the bipartisan Breast Cancer and Environmental Research Act, because it pursues the comprehensive strategy necessary for better understanding the links between the environment and breast cancer.

NBCC thanks the following Members for their leadership in helping to move the Breast Cancer and Environmental Research Act forward in the 107th Congress:

Senate:

- **Senators Harry Reid (D-NV), Lincoln Chafee (R-RI), Patrick Leahy (D-VT), and Orrin Hatch (R-UT):** Introduced S. 830, the Breast Cancer and Environmental Research Act in the Senate. Senator Reid, in his capacity as a Member of the Senate Appropriations Committee, worked to include language in the Senate Appropriations Committee's Labor HHS Committee Report that supports the intent of S. 830.
- **Senate Subcommittee on Labor Health and Human Services Chairman Tom Harkin (D-IA) and Ranking Member Arlen Specter (R-PA):** Included strong language in the Labor HHS Committee Report for fiscal year 2002 in support of the goals of S. 830.
- **Senator Hillary Rodham Clinton (D-NY):** For agreeing to offer S. 830 as an amendment at a Senate Health, Education, Labor and Pensions Committee markup.
- NBCC would also like to thank the **Senate Environment and Public Works Committee**, and especially **Senator Hillary Rodham Clinton (D-NY)**, for holding a field hearing in Long Island, New York on breast cancer and the environment and for including the Breast Cancer and Environmental Research Act as one of the issues discussed.

House:

- **Representatives Nita Lowey (D-NY) and Sue Myrick (R-NC):** introduced H.R. 1723, the Breast Cancer and Environmental Research Act in the House of Representatives.

Support for the Genetic Nondiscrimination in Health Insurance and Employment Act (S. 318/H.R. 602)

Goal: To enact S. 318/H.R. 602, the Genetic Nondiscrimination in Health Insurance and Employment Act that would prohibit health insurance and employment discrimination based on genetic information.

What We Asked

Members of

Congress

To Do: NBCC urged Members of Congress to sign on as co-sponsors to S. 318/H.R. 602, the Genetic Nondiscrimination in Health Insurance and Employment Act, and to enact this legislation into law this year.

What This Voter Guide

Records: Members receive a ✓ in the Voting Record for cosponsoring S. 318/H.R. 602.

Status: H.R. 602 was referred to the House Commerce Subcommittee on Health and Environment, the House Education and the Workforce Subcommittee on Employer-Employee Relations and the House Committee on Ways and Means. There are currently 266 cosponsors in the House of this bipartisan bill.

S. 318 was referred to the Senate Committee on Health, Education, Labor and Pensions and currently has 29 cosponsors.

As the mapping of the human genome continues to progress and new genetic tests are developed, the National Breast Cancer Coalition believes strongly that legislative and regulatory strategies must be established to address the protection of individuals from the misuse of their genetic information. Improper disclosure can lead to significant harm, including discrimination in the areas of employment and health insurance.

S. 318/H.R. 602, the Genetic Nondiscrimination in Health Insurance and Employment Act, would go beyond the protections offered in the Kassebaum-Kennedy Health Insurance Reform Act of 1996 by extending protections against misuse of genetic information to all health plans - both federally-regulated and state-regulated insurance - as well as government, church, individual and Medicare supplemental coverage policies. It would also extend protections to the employment arena. Passage of this bill would prohibit health plans and employers from discriminating against individuals based on their private genetic information.

NBCC recognizes the outstanding leadership of the following Members of Congress who helped to move the genetic nondiscrimination issue forward:

Senate:

- **Senator Tom Daschle (D-SD):** Lead Senate sponsor of S. 318, the Genetic Non-discrimination in Health Insurance and Employment Act.

- **Senate Health, Education, Labor and Pensions Chairman Ted Kennedy (D-MA):** Original co-sponsor of S. 318, and Chairman of the Senate Health, Education, Labor and Pensions Committee, which held a number of hearings on genetic information in the 107th Congress.
- * **Note:** NBCC could not support **Senator John Ensign's (R-NV)** genetic nondiscrimination amendment No. 849 (offered to the Senate passed patients' bill of rights, S. 1052) or **Senator Snowe's (R-ME)** genetic nondiscrimination bill (S. 1995) because we do not believe they go far enough to ensure that patients would be able to enforce the protections in this legislation. With regard to Senator Ensign's provision, we were also concerned that it offered protections in the health arena, but not in the employment arena. While NBCC appreciates Senators Ensign and Snowe's efforts to address the issue of genetic discrimination, we believe that without strong enforcement mechanisms, this legislation would fail to adequately protect individuals.

House:

- **Representatives Louise Slaughter (D-NY) and Connie Morella (R-MD):** Lead House sponsors of H.R. 602, the Genetic Nondiscrimination in Health Insurance and Employment Act.

**Support for S. 1052/H.R. 2563,
the Bipartisan Patient Protection Act**

Goal: To enact S. 1052/H.R. 2563, the Bipartisan Patient Protection Act, sponsored by **Representatives Greg Ganske (R-IA) and John Dingell (D-MI) and Senators John McCain (R-AZ) and Ted Kennedy (D-MA)**, which would protect the rights of women and their families.

What NBCC Asked

Members of

Congress

To Do: Vote only in favor of real patient protections that cover all individuals in private health plans, and include a strong enforcement mechanism with a right to sue in state and federal court.

What This

Voter Guide

Records: Representatives receive a ✓ in the Voter Guide for voting in favor of S.1052 and against the amendment H.Amdt. 303 to H.R. 2563 (this amendment rendered H.R. 2563 unenforceable by severely limiting patients' rights to sue if protections are denied).

Status: S. 1052 passed the Senate on June 29, 2001 with a vote of 59-36. The vote was primarily along party lines, with nine Republicans voting with 50 Democrats in favor of this bill.

H.R. 2563 was brought up on the House floor for a vote on August 2. An amendment was offered by Representative Charles Norwood (H.Amdt. 303) and passed 218-213. It also passed primarily along party lines, with only three Democrats voting for it, and only six Republicans voting against it. The House of Representatives then passed a weakened version of the Ganske-Dingell-Norwood Patient Protection Act by a vote of 226-203 (H.R. 2563 as amended).

NBCC supports passage of comprehensive legislation that would make quality health care available and accessible to everyone. Our goal is a dynamic healthcare system that recognizes quality, appropriately manages cost, and supports research.

Short of access to high quality health care for all women, we believe that breast cancer patients in private health plans have fundamental rights including: coverage for routine health costs associated with participation in clinical trials; the right to receive accurate information about their health plans; access to the right providers; involvement in treatment decisions that are based on good science; and confidentiality of their health information.

We also believe that any patient protection bill must include a strong enforceable mechanism with a right to sue in state and federal court. Under the current law, managed care companies can only be held accountable for the cost of the benefit it should have provided in the first place. This does no good if a patient has died, or if a patient has suffered grave loss as a result of denial of care. While the debate over patient protections should not be about lawsuits and remedies, it is essential that it be about how to ensure that breast cancer patients, and all patients, are guaranteed access to the quality care they need. If health plans comply with the law then those enforcement mechanisms will never have to be used. As patients, we need to know that these mechanisms are in place for our protection.

Although patient protection bills were passed in the House and the Senate in the 107th Congress, only the Senate passed bill would provide patients with a strong and accessible enforcement process that would allow them to uphold their rights. Representative Norwood's amendment to the House bill made that bill too difficult for patients' to enforce their rights, and therefore, NBCC could not support it.

While NBCC was disappointed that the differences between these bills could not be reconciled, we look forward to working with Members of Congress in the 108th Congress to enact a comprehensive and enforceable patients' protection bill.

NBCC recognizes the leadership of the following Members of Congress in the debate on furthering passage of meaningful patient protections:

Senate:

- **Senators Ted Kennedy (D-MA) and John McCain (R-AZ):** Lead Senate sponsors of S.1052, which passed the Senate by a vote of 59-36.

House:

- **Representatives Greg Ganske (R-IA) and John Dingell (D-MI):** Lead House sponsors of H.R. 2563, the House companion bill to S. 1052, which was severely weakened and unfortunately passed as amended on the House floor.

The House and Senate bills have now been referred to a Conference Committee.

A NOTE ABOUT ENFORCEMENT:

The National Breast Cancer Coalition believes that any legislation affording rights and privileges to individuals must have strong enforcement mechanisms to be effective. NBCC's general position is that a right without appropriate enforcement is no right at all.

In the area of patient protection, for instance, we believe that a strong enforcement provision must include: the right to hold insurance plans accountable in a court of law and the right to full compensation for injuries caused when patients' rights are violated. The need for strong enforcement mechanisms exists in the area of discrimination based on genetic information, and would apply in the context of all sets of patient protections.

We consider "full compensation" to include compensation for economic and non-economic damages. Moreover, it is our position that the mere threat of punitive damages deters insurance companies and providers from violating the law, and denying care. We are not on the side of the trial lawyers – and we are not on the side of the insurance companies. Rather, we are on the side of patients, and believe that individuals must be able to enforce the protections given to them by law in order to make those protections meaningful.

When patients are diagnosed with breast cancer, the last thing they want while they fight for their lives is to have to go to court and fight for their care. We have a responsibility to work together to improve patients' outcomes in the healthcare system so that they don't need to turn to the courts to access care.

When the House Energy and Commerce Committee held a hearing in July of 2002 to determine whether excessive litigation is harming patient access to care, NBCC testified that rather than focusing on whether litigation has increased, and whether jury awards are too high, the more important questions are: What type of care do patients deserve? Why are they turning to the court system to get it? Will limited accountability and capping damages solve the problem? NBCC is committed to ensuring a patient-centered, fair and transparent system of accountability for health care. There is no doubt that accountability can be a powerful deterrent, and that it is an essential component of change.

OTHER LEGISLATIVE INITIATIVES SUPPORTED BY NBCC:

In addition to the Coalition's legislative priorities, there were also a few initiatives in the 107th Congress that we want to highlight as important steps toward increasing high quality health care for low-income, uninsured women diagnosed with breast cancer.

First, the National Breast Cancer Coalition wants to thank **Senators Jeff Bingaman (D-NM) and John McCain (R-AZ) and Representatives Tom Udall (D-NM), J.D. Hayworth (R-AZ), Dale Kildee (D-MI) and J.C. Watts (R-OK)** for their leadership on S. 1741, the Native American Breast and Cervical Cancer Treatment Technical Amendment Act of 2001 (P.L. 107-121). This important legislation passed the Senate on November 28, 2001 by unanimous consent, and passed the House of Representatives on December 20, 2001. The President signed it into law this year.

This bill makes a simple but extremely important technical change to the Breast and Cervical Cancer Treatment and Prevention Act (P.L. 106-354) to ensure coverage of breast and cervical cancer treatment for American Indian and Alaskan Native women.

Enactment of the Breast and Cervical Cancer Treatment Act gave states the option to extend coverage to certain women who have been screened by programs operated under Title XV of the Public Health Service Act (the National Breast and Cervical Cancer Early Detection Program) and who have no creditable coverage.

While Congress' intent in enacting the Breast and Cervical Cancer Treatment Act was to ensure that states would have the option of providing Medicaid coverage to all low-income women screened and diagnosed with breast and cervical cancer through the Early Detection Program, the inclusion of a 'creditable coverage' standard [as defined by the Health Insurance Portability and Accountability Act (HIPAA) (1996) (P.L. 104-191)] inadvertently rendered American Indian and Alaskan Native women unqualified for coverage of critical care.

This legislation resolved these problems by clarifying that, for purposes of the Breast and Cervical Cancer Treatment Act, the term 'creditable coverage' does not include IHS-funded care so that American Indian and Alaska Native women can be covered by Medicaid for breast and cervical cancer treatment. With passage of this important correction, low-income American Indian and Alaska Native women diagnosed with breast and cervical cancer through federal screening programs have access to the care they deserve.

NBCC's attention and efforts continue to be focused on working with individual states to ensure that low-income women screened and diagnosed through the Centers for Disease Control and Prevention (CDC) National Breast and Cervical Cancer Early Detection Program will be guaranteed treatment. With the leadership of NBCC's grassroots advocates, 46 states have opted into the Breast and Cervical Cancer Treatment Program. Those states that have not yet opted in include: Kentucky, Massachusetts, New Mexico, and Oklahoma.

Second, NBCC appreciates **Senators Tom Daschle (D-SD) and Max Baucus (D-MT) and Representatives Richard Gephardt (D-MO) and John Dingell (D-MI)**, for their leadership on an economic stimulus package that would include a proposal to allow states to get temporary additional financial assistance to cover uninsured individuals in Medicaid.

In addition to allowing states to temporarily cover the newly uninsured in Medicaid, this package, known as the FMAP amendment, would (1) hold states harmless that were scheduled to see a reduction in their federal assistance this year; (2) provide an immediate 1.5% across the board increase in federal assistance to help meet increases in enrollment due to recession; and (3) provide an additional 1.5% increase in federal financial assistance for those states with particularly high unemployment.

Third, while the economic stimulus package was not enacted in the 107th Congress, there were various attempts, led by **Senators Collins (R-ME) and Rockefeller (D-WV), and Representatives Brown (D-OH), King (R-NY) and Shimkus (R-IL)**, to give necessary financial assistance to states to cover uninsured individuals. While legislation to achieve this goal was passed in the Senate, it was not ultimately taken up by the House, and therefore remained unfinished in the 107th Congress.

Finally, the National Breast Cancer Coalition remains committed to furthering high quality research into the cause of, optimal treatment, and cure for breast cancer through increased funding, improved coordination and distribution of research funds, and recruitment and training of scientists. NBCC is equally committed to making certain that the system to allocate those funds is transparent and accountable to the American public, and that the federal research dollars are allocated appropriately.

NBCC plans to work with Congress to create mechanisms to ensure a higher level of accountability for breast cancer research with federally appropriated funds. Answers to questions regarding how the money is being spent and whether it is being spent well are critical.

A NOTE ABOUT QUALITY CARE:

NBCC has been fighting for access to quality breast cancer care since its inception in 1991. We have been fortunate to work alongside Members of Congress who are committed to achieving similar goals – specifically **Senators Ted Kennedy (D-MA) and Bill Frist (R-TN)** with whom we have collaborated with on working toward the enactment of meaningful quality cancer care legislation.

While issues of expanding access to, financing and delivering health care are critical issues, NBCC believes that the struggle for increased access begs the questions: What care should we demand? What is quality care?

Part of the challenge in drafting “quality care” legislation is deciding what “quality care” actually means. Currently, there is no national consensus on what makes breast cancer care “quality care.” But even without a precise definition, we know that breast cancer care in this country is inconsistent and sometimes dangerously inadequate.

NBCC believes that everyone affected by breast cancer should have full access to the best care available, care that is based on sound scientific evidence and delivered in a respectful and timely manner.

We also know that more care is not always better care. We do not want to waste our limited resources – or risk our health or lives – on treatments that have not been shown to help. We deserve health care that works, and access to a wide range of well-designed and efficiently run clinical trials that help us find better treatments for breast cancer.

But evidence-based care is just one part of quality breast cancer care. Because we do not have a sure cure, breast cancer patients and clinicians are often forced to make crucial choices with inadequate information. Sometimes there are no best answers. In such uncertain and frightening environments, honest and respectful communication between doctors and patients becomes paramount.

For these reasons, NBCC does not view quality care as simply a checklist of procedures or a measurement of over-treatment and under-treatment. Instead, our vision is of overlapping core values that include:

- **access** to affordable health care,
- accurate, timely, and readily accessible **information** about treatment options based on evidence,
- **choice** about what course of treatment patients pursue, patient-centered and culturally respectful care,
- **accountability** in the health care system: national standards of quality that are determined by a decision-making body that includes consumers and that is continually updated, and
- ongoing commitment to **improving** the health care system by increasing the quality and quantity of available evidence, especially regarding the causes and prevention of breast cancer, and with an emphasis on learning from mistakes.

The specific methods and strategies for fulfilling these core values will vary, but the core values themselves will not. Together, they serve as a guide to design and evaluate quality health care public policy. We believe that successfully incorporating all of these core values into our health care system is the key to achieving quality breast cancer care.

WHERE DO WE GO FROM HERE

At the outset of the 108th Congress, the Board of the National Breast Cancer Coalition will set forth priorities for 2003.

In looking ahead to the next year, it will be NBCC's goal to continue working with Members of Congress towards maintaining the highly successful DoD BCRP, ensuring that breast cancer patients have access to the high quality treatment they need and deserve, and securing the meaningful involvement of consumers wherever important decisions affecting breast cancer patients are made.

In the 108th Congress, NBCC will also be continuing to look for ways to improve on our reflection of the work that Members of Congress do – both publicly and behind the scenes. While we will continue to expect co-sponsorship as a first demonstration of support for our agenda, we will seek opportunities to work with Members of Congress in the leadership, on relevant committees, or with a particular interest in breast cancer policy to go beyond simply co-sponsoring a bill. We will maintain our focus on applauding Members for the work they do behind the scenes – seeking ways to help communicate to their constituents the important work that they do on behalf of eradicating breast cancer. You can also expect that we will continue to be rigorous in holding Members accountable for their failure to support a substantive breast cancer agenda. And, as always, we remain committed to reflecting Members' stances only on the priority issues NBCC believes are most likely to move us forward in ending this disease. We do not attempt to reflect everything that Members of Congress do towards this end, but we do our best to illustrate the most important and significant actions taken.

We remain grateful for the hard work you have done and continue to do. We welcome your efforts in joining us to eradicate breast cancer.

Please do not hesitate to refer to our website at www.stopbreastcancer, or to contact us directly at 1-800-622-2838 for additional information.

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
AK	Sen. Ted Stevens (R)		✓			
AK	Sen. Frank H. Murkowski (R)	✓	✓			N/V
AK	Rep. Don Young (R-01)	✓	✓			
AL	Sen. Richard C. Shelby (R)					
AL	Sen. Jeff Sessions (R)					
AL	Rep. Earl F. Hilliard (D-07)	✓			✓	✓
AL	Rep. Sonny Callahan (R-01)		✓			
AL	Rep. Terry Everett (R-02)					
AL	Rep. Bob Riley (R-03)		✓			
AL	Rep. Robert B. Aderholt (R-04)					
AL	Rep. Robert E. Cramer Jr. (D-05)		✓		✓	✓
AL	Rep. Spencer Bachus (R-06)		✓		✓	
AR	Sen. Tim Hutchinson (R)		✓			
AR	Sen. Blanche Lambert Lincoln (D)	✓	✓			✓
AR	Rep. Marion Berry (D-01)		✓		✓	✓
AR	Rep. Vic Snyder (D-02)	✓	✓		✓	✓
AR	Rep. John N. Boozman (R-03)					
AR	Rep. Mike Ross (D-04)		✓			✓
AS	Rep. Eni F. H. Faleomavaega (D-01)					
AZ	Sen. John McCain (R)					✓
AZ	Sen. Jon L. Kyl (R)					
AZ	Rep. Bob Stump (R-03)		✓			
AZ	Rep. John B. Shadegg (R-04)		✓			
AZ	Rep. Jim Kolbe (R-05)		✓		✓	
AZ	Rep. J. D. Hayworth (R-06)	✓	✓			
AZ	Rep. Jeff Flake (R-01)					
AZ	Rep. Ed Pastor (D-02)	✓	✓	✓	✓	✓
CA	Sen. Dianne Feinstein (D)	✓	✓	✓		✓
CA	Sen. Barbara Boxer (D)	✓	✓	✓	✓	✓
CA	Rep. Mike Thompson (D-01)	✓	✓	✓	✓	✓
CA	Rep. Wally Herger (R-02)					
CA	Rep. Doug Ose (R-03)	✓	✓			
CA	Rep. John T. Doolittle (R-04)		✓			
CA	Rep. Robert T. Matsui (D-05)	✓	✓	✓	✓	✓
CA	Rep. Lynn C. Woolsey (D-06)	✓	✓	✓	✓	✓
CA	Rep. George Miller (D-07)	✓	✓	✓	✓	✓
CA	Rep. Nancy Pelosi (D-08)	✓	✓	✓	✓	✓
CA	Rep. Barbara Lee (D-09)	✓	✓	✓	✓	✓
CA	Rep. Ellen O. Tauscher (D-10)	✓		✓	✓	✓

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
CA	Rep. Richard W. Pombo (R-11)		✓			
CA	Rep. Tom Lantos (D-12)		✓	✓	✓	✓
CA	Rep. Fortney Pete Stark (D-13)	✓		✓	✓	✓
CA	Rep. Anna G. Eshoo (D-14)	✓	✓	✓	✓	✓
CA	Rep. Michael M. Honda (D-15)	✓	✓		✓	✓
CA	Rep. Zoe Lofgren (D-16)	✓	✓	✓	✓	✓
CA	Rep. Sam Farr (D-17)		✓	✓	✓	✓
CA	Rep. Gary A. Condit (D-18)	✓			✓	✓
CA	Rep. George Radanovich (R-19)					
CA	Rep. Calvin M. Dooley (D-20)	✓	✓	✓		✓
CA	Rep. William M. Thomas (R-21)	✓				
CA	Rep. Lois Capps (D-22)	✓	✓	✓	✓	✓
CA	Rep. Elton Gallegly (R-23)	✓	✓		✓	
CA	Rep. Brad Sherman (D-24)	✓	✓	✓	✓	✓
CA	Rep. Howard P. McKeon (R-25)		✓			
CA	Rep. Howard L. Berman (D-26)	✓	✓	✓	✓	✓
CA	Rep. Adam B. Schiff (D-27)	✓	✓	✓	✓	✓
CA	Rep. David Dreier (R-28)					
CA	Rep. Henry A. Waxman (D-29)	✓	✓	✓	✓	✓
CA	Rep. Xavier Becerra (D-30)	✓		✓	✓	✓
CA	Rep. Hilda L. Solis (D-31)	✓		✓	✓	✓
CA	Rep. Diane E. Watson (D-32)	✓	✓			✓
CA	Rep. Lucille Roybal-Allard (D-33)	✓	✓	✓	✓	✓
CA	Rep. Grace F. Napolitano (D-34)	✓	✓	✓	✓	✓
CA	Rep. Maxine Waters (D-35)	✓		✓	✓	✓
CA	Rep. Jane Harman (D-36)	✓	✓	✓	✓	✓
CA	Rep. Juanita Millender-McDonald (D-37)	✓	✓	✓	✓	✓
CA	Rep. Stephen Horn (R-38)	✓	✓	✓	✓	
CA	Rep. Edward R. Royce (R-39)					
CA	Rep. Jerry Lewis (R-40)					
CA	Rep. Gary G. Miller (R-41)	✓				
CA	Rep. Joe Baca (D-42)	✓	✓	✓	✓	✓
CA	Rep. Ken Calvert (R-43)				✓	
CA	Rep. Mary Bono (R-44)				✓	
CA	Rep. Dana Rohrabacher (R-45)					
CA	Rep. Loretta Sanchez (D-46)	✓	✓		✓	✓
CA	Rep. Christopher Cox (R-47)					
CA	Rep. Darrell E. Issa (R-48)		✓			
CA	Rep. Susan A. Davis (D-49)	✓	✓	✓	✓	✓
CA	Rep. Bob Filner (D-50)	✓	✓	✓	✓	✓
CA	Rep. Randy Cunningham (R-51)		✓			
CA	Rep. Duncan Hunter (R-52)		✓			
CO	Sen. Ben Nighthorse Campbell (R)		✓			N/V

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
CO	Sen. Wayne A. Allard (R)					
CO	Rep. Diana DeGette (D-01)	✓	✓		✓	✓
CO	Rep. Mark Udall (D-02)	✓	✓	✓	✓	✓
CO	Rep. Scott McInnis (R-03)	✓				
CO	Rep. Bob Schaffer (R-04)		✓			
CO	Rep. Joel Hefley (R-05)		✓	✓	✓	
CO	Rep. Thomas G. Tancredo (R-06)					
CT	Sen. Christopher J. Dodd (D)	✓	✓	✓	✓	✓
CT	Sen. Joseph I. Lieberman (D)	✓	✓	✓	✓	✓
CT	Rep. John B. Larson (D-01)	✓	✓	✓	✓	✓
CT	Rep. Rob Simmons (R-02)	✓	✓	✓	✓	
CT	Rep. Rosa L. DeLauro (D-03)	✓	✓	✓	✓	✓
CT	Rep. Christopher Shays (R-04)	✓	✓	✓	✓	
CT	Rep. James H. Maloney (D-05)	✓	✓	✓	✓	✓
CT	Rep. Nancy L. Johnson (R-06)	✓				
DC	Rep. Eleanor Holmes Norton (D-01)	✓	✓	✓	✓	
DE	Sen. Thomas R. Carper (D)		✓			✓
DE	Sen. Joseph R. Biden Jr. (D)	✓	✓	✓	✓	✓
DE	Rep. Michael N. Castle (R-01)	✓	✓			
FL	Sen. Bob Graham (D)	✓				✓
FL	Sen. Bill Nelson (D)	✓	✓			✓
FL	Rep. Jefferson B. Miller (R-01)					
FL	Rep. Allen Boyd Jr. (D-02)		✓		✓	✓
FL	Rep. Corrine Brown (D-03)	✓	✓	✓	✓	✓
FL	Rep. Ander Crenshaw (R-04)		✓			
FL	Rep. Karen L. Thurman (D-05)	✓	✓	✓	✓	✓
FL	Rep. Cliff Stearns (R-06)		✓			
FL	Rep. John L. Mica (R-07)	✓	✓		✓	
FL	Rep. Ric Keller (R-08)		✓			
FL	Rep. Michael Bilirakis (R-09)	✓				
FL	Rep. C. W. Young (R-10)					
FL	Rep. Jim Davis (D-11)	✓		✓	✓	✓
FL	Rep. Adam H. Putnam (R-12)	✓	✓			
FL	Rep. Dan Miller (R-13)				✓	
FL	Rep. Porter J. Goss (R-14)					
FL	Rep. Dave Weldon (R-15)		✓			
FL	Rep. Mark Foley (R-16)		✓		✓	
FL	Rep. Carrie P. Meek (D-17)	✓	✓		✓	✓
FL	Rep. Ileana Ros-Lehtinen (R-18)	✓	✓	✓	✓	
FL	Rep. Robert Wexler (D-19)	✓	✓	✓	✓	✓
FL	Rep. Peter Deutsch (D-20)	✓	✓	✓		✓
FL	Rep. Lincoln Diaz-Balart (R-21)	✓	✓	✓		
FL	Rep. E. Clay Shaw Jr. (R-22)	✓	✓			

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
FL	Rep. Alcee L. Hastings (D-23)	✓	✓		✓	✓
GA	Sen. Max Cleland (D)	✓	✓		✓	✓
GA	Sen. Zell B. Miller (D)		✓			✓
GA	Rep. Jack Kingston (R-01)		✓			
GA	Rep. Sanford D. Bishop Jr. (D-02)		✓	✓	✓	✓
GA	Rep. Mac Collins (R-03)					
GA	Rep. Cynthia A. McKinney (D-04)		✓	✓	✓	✓
GA	Rep. John Lewis (D-05)		✓		✓	✓
GA	Rep. Johnny Isakson (R-06)	✓	✓			
GA	Rep. Bob Barr Jr. (R-07)					
GA	Rep. Saxby Chambliss (R-08)		✓			
GA	Rep. Nathan Deal (R-09)					
GA	Rep. Charlie Norwood Jr. (R-10)	✓		✓		
GA	Rep. John Linder (R-11)					
GU	Rep. Robert A. Underwood (D-01)	✓	✓		✓	
HI	Sen. Daniel K. Inouye (D)		✓		✓	✓
HI	Sen. Daniel K. Akaka (D)	✓				✓
HI	Rep. Neil Abercrombie (D-01)	✓	✓	✓	✓	✓
HI	Rep. Patsy T. Mink (D-02) <i>died 9/28/02</i>	✓	✓	✓	✓	✓
IA	Sen. Charles E. Grassley (R)	✓		✓		
IA	Sen. Tom Harkin (D)	✓		✓	✓	✓
IA	Rep. James A. Leach (R-01)	✓	✓	✓	✓	✓
IA	Rep. Jim Nussle (R-02)			✓		
IA	Rep. Leonard L. Boswell (D-03)	✓		✓	✓	✓
IA	Rep. Greg Ganske (R-04)	✓	✓	✓		✓
IA	Rep. Tom Latham (R-05)		✓	✓		
ID	Sen. Larry Craig (R)		✓			
ID	Sen. Michael D. Crapo (R)		✓			
ID	Rep. C. L. Otter (R-01)					
ID	Rep. Michael K. Simpson (R-02)		✓			
IL	Sen. Richard J. Durbin (D)	✓	✓		✓	✓
IL	Sen. Peter G. Fitzgerald (R)	✓	✓	✓		✓
IL	Rep. Bobby L. Rush (D-01)	✓	✓	✓	✓	✓
IL	Rep. Jesse L. Jackson Jr. (D-02)	✓	✓	✓	✓	✓
IL	Rep. William O. Lipinski (D-03)	✓	✓	✓	✓	N/V
IL	Rep. Luis V. Gutierrez (D-04)	✓	✓	✓	✓	✓
IL	Rep. Rod R. Blagojevich (D-05)	✓	✓	✓	✓	✓
IL	Rep. Henry J. Hyde (R-06)		✓		✓	
IL	Rep. Danny K. Davis (D-07)	✓	✓	✓	✓	✓
IL	Rep. Philip M. Crane (R-08)					
IL	Rep. Janice D. Schakowsky (D-09)	✓	✓	✓	✓	✓
IL	Rep. Mark Steven Kirk (R-10)	✓	✓	✓	✓	
IL	Rep. Jerry Weller (R-11)	✓	✓			

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
IL	Rep. Jerry F. Costello (D-12)	✓	✓	✓	✓	✓
IL	Rep. Judy Biggert (R-13)	✓	✓	✓	✓	
IL	Rep. J. Dennis Hastert (R-14)					
IL	Rep. Timothy V. Johnson (R-15)	✓	✓			✓
IL	Rep. Donald A. Manzullo (R-16)	✓	✓			
IL	Rep. Lane Evans (D-17)	✓	✓	✓	✓	✓
IL	Rep. Ray LaHood (R-18)		✓	✓	✓	
IL	Rep. David D. Phelps (D-19)	✓	✓	✓	✓	✓
IL	Rep. John Shimkus (R-20)	✓	✓			
IN	Sen. Richard G. Lugar (R)					
IN	Sen. B. Evan Bayh (D)	✓	✓	✓		✓
IN	Rep. Peter J. Visclosky (D-01)				✓	✓
IN	Rep. Mike Pence (R-02)		✓			
IN	Rep. Tim Roemer (D-03)			✓	✓	✓
IN	Rep. Mark E. Souder (R-04)		✓		✓	
IN	Rep. Steve Buyer (R-05)					
IN	Rep. Dan Burton (R-06)		✓	✓	✓	
IN	Rep. Brian D. Kerns (R-07)		✓	✓		
IN	Rep. John N. Hostettler (R-08)		✓			
IN	Rep. Baron P. Hill (D-09)			✓		✓
IN	Rep. Julia Carson (D-10)	✓	✓	✓	✓	✓
KS	Sen. Sam Brownback (R)		✓			
KS	Sen. Pat Roberts (R)		✓			
KS	Rep. Jerry Moran (R-01)		✓			
KS	Rep. Jim Ryun (R-02)		✓			
KS	Rep. Dennis Moore (D-03)	✓	✓	✓	✓	✓
KS	Rep. Todd Tiahrt (R-04)		✓		✓	
KY	Sen. Mitch McConnell (R)	✓				
KY	Sen. Jim Bunning (R)					
KY	Rep. Ed Whitfield (R-01)	✓	✓			
KY	Rep. Ron Lewis (R-02)					
KY	Rep. Anne M. Northup (R-03)				✓	
KY	Rep. Ken Lucas (D-04)		✓	✓	✓	
KY	Rep. Harold Rogers (R-05)					
KY	Rep. Ernie Fletcher (R-06)					
LA	Sen. John B. Breaux (D)	✓				✓
LA	Sen. Mary L. Landrieu (D)	✓	✓	✓		✓
LA	Rep. David Vitter (R-01)		✓	✓		
LA	Rep. William J. Jefferson (D-02)	✓	✓	✓	✓	✓
LA	Rep. W. J. Tauzin (R-03)					
LA	Rep. Jim McCrery (R-04)					
LA	Rep. John Cooksey (R-05)	✓			✓	
LA	Rep. Richard H. Baker (R-06)			✓	✓	

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
LA	Rep. Christopher John (D-07)		✓			✓
MA	Sen. Edward M. Kennedy (D)	✓	✓	✓	✓	✓
MA	Sen. John F. Kerry (D)	✓	✓	✓	✓	✓
MA	Rep. John W. Oliver (D-01)	✓	✓	✓	✓	✓
MA	Rep. Richard E. Neal (D-02)	✓	✓	✓	✓	✓
MA	Rep. James P. McGovern (D-03)	✓	✓	✓	✓	✓
MA	Rep. Barney Frank (D-04)	✓	✓	✓	✓	✓
MA	Rep. Martin T. Meehan (D-05)	✓	✓	✓	✓	✓
MA	Rep. John F. Tierney (D-06)	✓	✓		✓	✓
MA	Rep. Edward J. Markey (D-07)	✓		✓	✓	✓
MA	Rep. Michael E. Capuano (D-08)	✓	✓	✓	✓	✓
MA	Rep. Stephen F. Lynch (D-09)	✓	✓	✓	✓	
MA	Rep. William D. Delahunt (D-10)	✓		✓	✓	✓
MD	Sen. Paul S. Sarbanes (D)	✓	✓		✓	✓
MD	Sen. Barbara A. Mikulski (D)	✓	✓	✓	✓	✓
MD	Rep. Wayne T. Gilchrest (R-01)	✓	✓		✓	
MD	Rep. Robert L. Ehrlich Jr. (R-02)	✓	✓	✓		
MD	Rep. Benjamin L. Cardin (D-03)		✓		✓	✓
MD	Rep. Albert Russell Wynn (D-04)	✓	✓	✓	✓	✓
MD	Rep. Steny H. Hoyer (D-05)		✓	✓	✓	✓
MD	Rep. Roscoe G. Bartlett (R-06)		✓			
MD	Rep. Elijah E. Cummings (D-07)	✓	✓	✓	✓	✓
MD	Rep. Constance A. Morella (R-08)	✓	✓	✓	✓	✓
ME	Sen. Olympia J. Snowe (R)	✓	✓	✓		✓
ME	Sen. Susan M. Collins (R)	✓	✓	✓		✓
ME	Rep. Thomas H. Allen (D-01)	✓	✓	✓	✓	✓
ME	Rep. John Elias Baldacci (D-02)	✓	✓	✓	✓	✓
MI	Sen. Carl Levin (D)	✓				✓
MI	Sen. Debbie Stabenow (D)	✓	✓	✓	✓	✓
MI	Rep. Bart Stupak (D-01)	✓	✓	✓	✓	✓
MI	Rep. Peter Hoekstra (R-02)					
MI	Rep. Vernon J. Ehlers (R-03)					
MI	Rep. Dave Camp (R-04)	✓	✓			
MI	Rep. James A. Barcia (D-05)	✓	✓		✓	✓
MI	Rep. Fred Upton (R-06)	✓			✓	
MI	Rep. Nick Smith (R-07)					
MI	Rep. Mike Rogers (R-08)		✓			
MI	Rep. Dale E. Kildee (D-09)	✓	✓	✓	✓	✓
MI	Rep. David E. Bonior (D-10)	✓	✓	✓	✓	✓
MI	Rep. Joe Knollenberg (R-11)		✓			
MI	Rep. Sander M. Levin (D-12)	✓	✓		✓	✓
MI	Rep. Lynn N. Rivers (D-13)	✓	✓	✓	✓	✓
MI	Rep. John Conyers Jr. (D-14)	✓	✓		✓	✓

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
MI	Rep. Carolyn C. Kilpatrick (D-15)		✓		✓	✓
MI	Rep. John D. Dingell (D-16)	✓	✓	✓	✓	✓
MN	Sen. Paul Wellstone (D) <i>died 10/25/02</i>	✓		✓	✓	✓
MN	Sen. Mark Dayton (D)	✓		✓	✓	✓
MN	Rep. Gil Gutknecht Jr. (R-01)					
MN	Rep. Mark R. Kennedy (R-02)					
MN	Rep. Jim Ramstad (R-03)	✓	✓			
MN	Rep. Betty McCollum (D-04)	✓	✓	✓	✓	✓
MN	Rep. Martin Olav Sabo (D-05)		✓		✓	✓
MN	Rep. Bill Luther (D-06)	✓	✓	✓	✓	✓
MN	Rep. Collin C. Peterson (D-07)		✓	✓	✓	
MN	Rep. James L. Oberstar (D-08)	✓	✓	✓	✓	✓
MO	Sen. Christopher S. Bond (R)	✓				
MO	Sen. Jean Carnahan (D)	✓		✓		✓
MO	Rep. William Lacy Clay Jr. (D-01)	✓	✓	✓	✓	✓
MO	Rep. W. Todd Akin (R-02)					
MO	Rep. Richard A. Gephardt (D-03)	✓			✓	✓
MO	Rep. Ike Skelton (D-04)		✓	✓	✓	✓
MO	Rep. Karen McCarthy (D-05)	✓	✓		✓	✓
MO	Rep. Sam Graves (R-06)					
MO	Rep. Roy Blunt (R-07)		✓			
MO	Rep. Jo Ann Emerson (R-08)		✓			
MO	Rep. Kenny C. Hulshof (R-09)					
MS	Sen. Thad Cochran (R)		✓	✓		
MS	Sen. Trent Lott (R)					N/V
MS	Rep. Roger F. Wicker (R-01)	✓	✓		✓	
MS	Rep. Bennie G. Thompson (D-02)	✓	✓		✓	✓
MS	Rep. Charles W. Pickering Jr. (R-03)	✓	✓			
MS	Rep. Ronnie Shows (D-04)	✓	✓		✓	✓
MS	Rep. Gene Taylor (D-05)				✓	✓
MT	Sen. Max Baucus (D)	✓				✓
MT	Sen. Conrad Burns (R)		✓			
MT	Rep. Dennis R. Rehberg (R-01)		✓			
NC	Sen. Jesse Helms (R)	✓				
NC	Sen. John R. Edwards (D)	✓		✓	✓	✓
NC	Rep. Eva M. Clayton (D-01)	✓	✓		✓	✓
NC	Rep. Bob Etheridge (D-02)	✓	✓		✓	✓
NC	Rep. Walter B. Jones Jr. (R-03)	✓	✓			
NC	Rep. David E. Price (D-04)	✓	✓	✓	✓	✓
NC	Rep. Richard Burr (R-05)					
NC	Rep. Howard Coble (R-06)	✓				
NC	Rep. Mike McIntyre (D-07)	✓	✓	✓	✓	✓
NC	Rep. Robin Hayes (R-08)	✓				

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
NC	Rep. Sue Wilkins Myrick (R-09)	✓	✓	✓		
NC	Rep. Cass Ballenger (R-10)			✓		
NC	Rep. Charles H. Taylor (R-11)				✓	
NC	Rep. Melvin L. Watt (D-12)	✓	✓	✓	✓	✓
ND	Sen. Kent Conrad (D)					✓
ND	Sen. Byron L. Dorgan (D)		✓		✓	✓
ND	Rep. Earl Pomeroy (D-01)		✓		✓	✓
NE	Sen. E. Benjamin Nelson (D)	✓	✓	✓		✓
NE	Sen. Chuck Hagel (R)	✓	✓	✓		
NE	Rep. Doug Bereuter (R-01)			✓		
NE	Rep. Lee Terry (R-02)	✓	✓	✓		
NE	Rep. Tom Osborne (R-03)		✓	✓	✓	
NH	Sen. Robert C. Smith (R)					
NH	Sen. Judd Gregg (R)	✓				
NH	Rep. John E. Sununu (R-01)	✓	✓	✓		
NH	Rep. Charles F. Bass (R-02)	✓	✓	✓	✓	
NJ	Sen. Jon S. Corzine (D)	✓	✓	✓	✓	✓
NJ	Sen. Robert G. Torricelli (D)	✓	✓	✓	✓	✓
NJ	Rep. Robert E. Andrews (D-01)	✓	✓	✓	✓	✓
NJ	Rep. Frank A. LoBiondo (R-02)	✓	✓		✓	
NJ	Rep. Jim Saxton (R-03)	✓	✓	✓		
NJ	Rep. Christopher H. Smith (R-04)	✓	✓			✓
NJ	Rep. Marge Roukema (R-05)	✓	✓	✓	✓	✓
NJ	Rep. Frank Pallone Jr. (D-06)	✓	✓	✓	✓	✓
NJ	Rep. Mike Ferguson (R-07)	✓	✓	✓	✓	
NJ	Rep. Bill Pascrell Jr. (D-08)	✓	✓	✓	✓	✓
NJ	Rep. Steven R. Rothman (D-09)	✓	✓	✓	✓	✓
NJ	Rep. Donald M. Payne (D-10)	✓	✓	✓	✓	✓
NJ	Rep. Rodney P. Frelinghuysen (R-11)		✓		✓	
NJ	Rep. Rush D. Holt (D-12)	✓	✓	✓	✓	✓
NJ	Rep. Robert Menendez (D-13)	✓	✓	✓	✓	✓
NM	Sen. Pete V. Domenici (R)	✓				N/V
NM	Sen. Jeff Bingaman (D)	✓	✓	✓	✓	✓
NM	Rep. Heather Wilson (R-01)					
NM	Rep. Joe Skeen (R-02)		✓			
NM	Rep. Tom Udall (D-03)	✓	✓		✓	✓
NV	Sen. Harry Reid (D)	✓		✓	✓	✓
NV	Sen. John Ensign (R)	✓				
NV	Rep. Shelley Berkley (D-01)	✓	✓	✓	✓	✓
NV	Rep. Jim Gibbons (R-02)	✓			✓	
NY	Sen. Hillary Rodham Clinton (D)	✓	✓	✓	✓	✓
NY	Sen. Charles E. Schumer (D)	✓	✓	✓	✓	✓
NY	Rep. Felix J. Grucci Jr. (R-01)	✓	✓	✓	✓	

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
NY	Rep. Steve Israel (D-02)	✓	✓	✓	✓	✓
NY	Rep. Peter T. King (R-03)	✓	✓	✓	✓	
NY	Rep. Carolyn McCarthy (D-04)	✓	✓	✓	✓	✓
NY	Rep. Gary L. Ackerman (D-05)	✓	✓	✓	✓	✓
NY	Rep. Gregory W. Meeks (D-06)		✓		✓	✓
NY	Rep. Joseph Crowley (D-07)	✓	✓	✓	✓	✓
NY	Rep. Jerrold Nadler (D-08)	✓	✓	✓	✓	✓
NY	Rep. Anthony D. Weiner (D-09)	✓	✓	✓	✓	✓
NY	Rep. Edolphus Towns (D-10)		✓			✓
NY	Rep. Major R. Owens (D-11)	✓	✓	✓	✓	✓
NY	Rep. Nydia M. Velazquez (D-12)	✓	✓		✓	✓
NY	Rep. Vito Fossella (R-13)	✓				
NY	Rep. Carolyn B. Maloney (D-14)	✓	✓	✓	✓	✓
NY	Rep. Charles B. Rangel (D-15)	✓	✓	✓	✓	✓
NY	Rep. Jose E. Serrano (D-16)	✓	✓	✓	✓	✓
NY	Rep. Eliot L. Engel (D-17)	✓	✓	✓	✓	✓
NY	Rep. Nita M. Lowey (D-18)	✓	✓	✓	✓	✓
NY	Rep. Sue W. Kelly (R-19)	✓	✓	✓	✓	
NY	Rep. Benjamin A. Gilman (R-20)		✓	✓	✓	
NY	Rep. Michael R. McNulty (D-21)	✓	✓	✓	✓	✓
NY	Rep. John E. Sweeney (R-22)	✓	✓	✓	✓	
NY	Rep. Sherwood L. Boehlert (R-23)	✓	✓			
NY	Rep. John M. McHugh (R-24)				✓	
NY	Rep. James T. Walsh (R-25)	✓	✓	✓	✓	
NY	Rep. Maurice D. Hinchey (D-26)	✓	✓	✓	✓	✓
NY	Rep. Thomas M. Reynolds (R-27)	✓	✓			
NY	Rep. Louise McIntosh Slaughter (D-28)	✓	✓		✓	✓
NY	Rep. John J. LaFalce (D-29)	✓	✓		✓	✓
NY	Rep. Jack Quinn (R-30)	✓	✓	✓	✓	
NY	Rep. Amo Houghton (R-31)		✓			
OH	Sen. Mike DeWine (R)	✓	✓	✓		✓
OH	Sen. George V. Voinovich (R)			✓		
OH	Rep. Steve Chabot (R-01)	✓				
OH	Rep. Rob Portman (R-02)	✓	✓			
OH	Rep. Tony P. Hall (D-03) <i>resigned 9/9/02</i>	✓	✓		✓	✓
OH	Rep. Michael G. Oxley (R-04)					
OH	Rep. Paul E. Gillmor (R-05)				✓	
OH	Rep. Ted Strickland (D-06)	✓	✓	✓	✓	✓
OH	Rep. David L. Hobson (R-07)		✓			
OH	Rep. John A. Boehner (R-08)					
OH	Rep. Marcy Kaptur (D-09)	✓	✓	✓	✓	✓
OH	Rep. Dennis J. Kucinich (D-10)	✓		✓	✓	✓
OH	Rep. Stephanie Tubbs Jones (D-11)	✓	✓	✓	✓	✓

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
OH	Rep. Patrick J. Tiberi (R-12)	✓	✓			
OH	Rep. Sherrod Brown (D-13)	✓	✓	✓	✓	✓
OH	Rep. Tom Sawyer (D-14)	✓	✓	✓	✓	✓
OH	Rep. Deborah Pryce (R-15)		✓			
OH	Rep. Ralph Regula (R-16)		✓		✓	
OH	Rep. James Traficant (D-17) <i>expelled 7/24/02</i>					
OH	Rep. Robert W. Ney (R-18)		✓		✓	
OH	Rep. Steven C. LaTourette (R-19)		✓		✓	
OK	Sen. Don Nickles (R)					
OK	Sen. James M. Inhofe (R)		✓			
OK	Rep. John A. Sullivan (R-01)					
OK	Rep. Brad Carson (D-02)	✓	✓		✓	✓
OK	Rep. Wes Watkins (R-03)		✓			
OK	Rep. J. C. Watts Jr. (R-04)	✓				
OK	Rep. Ernest J. Istook Jr. (R-05)					
OK	Rep. Frank D. Lucas (R-06)		✓			
OR	Sen. Ron Wyden (D)	✓				✓
OR	Sen. Gordon H. Smith (R)	✓	✓	✓		✓
OR	Rep. David Wu (D-01)	✓	✓		✓	✓
OR	Rep. Greg Walden (R-02)		✓			
OR	Rep. Earl Blumenauer (D-03)	✓	✓		✓	✓
OR	Rep. Peter A. DeFazio (D-04)	✓	✓	✓	✓	✓
OR	Rep. Darlene Hooley (D-05)	✓	✓	✓	✓	✓
PA	Sen. Arlen Specter (R)	✓	✓			✓
PA	Sen. Richard J. Santorum (R)					
PA	Rep. Robert A. Brady (D-01)	✓	✓	✓	✓	✓
PA	Rep. Chaka Fattah (D-02)		✓	✓	✓	✓
PA	Rep. Robert A. Borski (D-03)	✓	✓	✓	✓	✓
PA	Rep. Melissa A. Hart (R-04)	✓	✓		✓	
PA	Rep. John E. Peterson (R-05)		✓			
PA	Rep. Tim Holden (D-06)	✓	✓	✓	✓	✓
PA	Rep. Curt Weldon (R-07)		✓		✓	
PA	Rep. James C. Greenwood (R-08)	✓	✓		✓	
PA	Rep. William Shuster (R-09)		✓			
PA	Rep. Don Sherwood (R-10)		✓			
PA	Rep. Paul E. Kanjorski (D-11)				✓	✓
PA	Rep. John P. Murtha (D-12)		✓	✓	✓	✓
PA	Rep. Joseph M. Hoeffel III (D-13)	✓	✓	✓	✓	✓
PA	Rep. William J. Coyne (D-14)	✓	✓	✓	✓	✓
PA	Rep. Patrick J. Toomey (R-15)					
PA	Rep. Joseph R. Pitts (R-16)					
PA	Rep. George W. Gekas (R-17)		✓			
PA	Rep. Michael F. Doyle Jr. (D-18)	✓	✓	✓	✓	✓

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
PA	Rep. Todd Russell Platts (R-19)	✓	✓	✓	✓	
PA	Rep. Frank Mascara (D-20)	✓	✓	✓	✓	✓
PA	Rep. Phil English (R-21)	✓	✓			
PR	Rep. Anibal Acevedo-Vila (D-01)					
RI	Sen. John F. Reed (D)	✓	✓	✓	✓	✓
RI	Sen. Lincoln D. Chafee (R)	✓	✓	✓		✓
RI	Rep. Patrick J. Kennedy (D-01)	✓	✓	✓	✓	✓
RI	Rep. James R. Langevin (D-02)	✓	✓	✓	✓	✓
SC	Sen. Strom Thurmond (R)					
SC	Sen. Ernest F. Hollings (D)		✓			✓
SC	Rep. Henry E. Brown Jr. (R-01)					
SC	Rep. Addison Graves Wilson (R-02)		✓			
SC	Rep. Lindsey O. Graham (R-03)		✓			
SC	Rep. Jim DeMint (R-04)		✓			
SC	Rep. John M. Spratt Jr. (D-05)				✓	✓
SC	Rep. James E. Clyburn (D-06)	✓	✓		✓	✓
SD	Sen. Thomas A. Daschle (D)	✓	✓	✓	✓	✓
SD	Sen. Tim P. Johnson (D)	✓	✓	✓		✓
SD	Rep. John R. Thune (R-01)	✓	✓	✓		
TN	Sen. Fred D. Thompson (R)					
TN	Sen. Bill Frist (R)					
TN	Rep. William L. Jenkins (R-01)		✓	✓		
TN	Rep. John J. Duncan Jr. (R-02)		✓		✓	
TN	Rep. Zach Wamp (R-03)	✓	✓	✓	✓	
TN	Rep. Van Hilleary (R-04)		✓	✓		
TN	Rep. Bob Clement (D-05)	✓	✓	✓	✓	✓
TN	Rep. Bart Gordon (D-06)	✓	✓	✓	✓	✓
TN	Rep. Ed Bryant (R-07)		✓	✓		
TN	Rep. John S. Tanner (D-08)	✓	✓	✓		✓
TN	Rep. Harold E. Ford Jr. (D-09)	✓			✓	✓
TX	Sen. Phil Gramm (R)					N/V
TX	Sen. Kay Bailey Hutchison (R)	✓				
TX	Rep. Max Sandlin (D-01)	✓	✓		✓	✓
TX	Rep. Jim Turner (D-02)	✓	✓		✓	✓
TX	Rep. Sam Johnson (R-03)					
TX	Rep. Ralph M. Hall (D-04)		✓			✓
TX	Rep. Pete Sessions (R-05)	✓	✓			
TX	Rep. Joe Barton (R-06)		✓			
TX	Rep. John Abney Culberson (R-07)					
TX	Rep. Kevin Brady (R-08)		✓			
TX	Rep. Nick Lampson (D-09)			✓	✓	✓
TX	Rep. Lloyd Doggett (D-10)	✓			✓	✓

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
TX	Rep. Chet Edwards (D-11)		✓		✓	✓
TX	Rep. Kay Granger (R-12)				✓	
TX	Rep. Mac Thornberry (R-13)					
TX	Rep. Ron Paul (R-14)					N/V
TX	Rep. Ruben Hinojosa (D-15)	✓		✓	✓	✓
TX	Rep. Silvestre Reyes (D-16)		✓	✓	✓	✓
TX	Rep. Charles W. Stenholm (D-17)				✓	✓
TX	Rep. Sheila Jackson-Lee (D-18)	✓	✓	✓	✓	✓
TX	Rep. Larry Combest (R-19)					
TX	Rep. Charles A. Gonzalez (D-20)	✓	✓	✓	✓	✓
TX	Rep. Lamar S. Smith (R-21)	✓				
TX	Rep. Tom DeLay (R-22)					
TX	Rep. Henry Bonilla (R-23)	✓	✓	✓		
TX	Rep. Martin Frost (D-24)	✓	✓	✓	✓	✓
TX	Rep. Ken Bentsen Jr. (D-25)	✓	✓	✓	✓	✓
TX	Rep. Richard K. Armey (R-26)					
TX	Rep. Solomon P. Ortiz (D-27)	✓			✓	✓
TX	Rep. Ciro D. Rodriguez (D-28)	✓	✓	✓	✓	✓
TX	Rep. Gene Green (D-29)	✓	✓	✓	✓	✓
TX	Rep. Eddie Bernice Johnson (D-30)	✓	✓	✓	✓	✓
UT	Sen. Orrin G. Hatch (R)		✓	✓		
UT	Sen. Robert F. Bennett (R)		✓			
UT	Rep. James V. Hansen (R-01)					
UT	Rep. Jim Matheson (D-02)	✓	✓		✓	✓
UT	Rep. Chris Cannon (R-03)		✓			
VA	Sen. John William Warner (R)	✓	✓	✓		✓
VA	Sen. George F. Allen (R)	✓	✓	✓		
VA	Rep. Jo Ann Davis (R-01)		✓	✓	✓	
VA	Rep. Edward L. Schrock (R-02)		✓	✓		
VA	Rep. Robert C. Scott (D-03)	✓	✓		✓	✓
VA	Rep. James Randy Forbes (R-04)		✓			
VA	Rep. Virgil H. Goode Jr. (R-05)		✓			
VA	Rep. Bob Goodlatte (R-06)		✓		✓	
VA	Rep. Eric Cantor (R-07)		✓			
VA	Rep. James P. Moran (D-08)	✓	✓	✓	✓	✓
VA	Rep. Rick Boucher (D-09)		✓	✓	✓	✓
VA	Rep. Frank R. Wolf (R-10)		✓		✓	
VA	Rep. Thomas M. Davis (R-11)	✓	✓		✓	
VI	Rep. Donna Christensen MD (D-01)		✓		✓	
VT	Sen. Patrick J. Leahy (D)	✓		✓	✓	✓
VT	Sen. James M. Jeffords (I)	✓	✓	✓		
VT	Rep. Bernard Sanders (I-01)	✓	✓	✓	✓	✓
WA	Sen. Maria Cantwell (D)	✓	✓		✓	✓

State	Name	DOD Peer-Reviewed Breast Cancer Research Program "Dear Colleague Letter" for FY 2003	Access to Cancer Therapies Act Cosponsor HR 1624 / S 913	Environmental Research Act Cosponsor HR 1723 / S 830	Genetic Non-discrimination Cosponsor HR 602 / S 318	Bipartisan Patient Protection Act Vote for HR 2563 / S 1052
WA	Sen. Patty Murray (D)	✓		✓	✓	✓
WA	Rep. Jay Inslee (D-01)	✓	✓		✓	✓
WA	Rep. Rick Larsen (D-02)	✓	✓	✓	✓	✓
WA	Rep. Brian Baird (D-03)	✓	✓	✓	✓	✓
WA	Rep. Doc Hastings (R-04)					
WA	Rep. George R. Nethercutt Jr. (R-05)		✓			
WA	Rep. Norman D. Dicks (D-06)		✓		✓	✓
WA	Rep. Jim McDermott (D-07)	✓	✓		✓	✓
WA	Rep. Jennifer Dunn (R-08)		✓			
WA	Rep. Adam Smith (D-09)		✓		✓	✓
WI	Sen. Herbert H. Kohl (D)	✓		✓		✓
WI	Sen. Russ Feingold (D)	✓		✓	✓	✓
WI	Rep. Paul Ryan (R-01)	✓	✓			
WI	Rep. Tammy Baldwin (D-02)	✓	✓	✓	✓	✓
WI	Rep. Ron Kind (D-03)	✓	✓		✓	✓
WI	Rep. Gerald D. Kleczka (D-04)	✓		✓	✓	✓
WI	Rep. Thomas M. Barrett (D-05)	✓	✓	✓	✓	✓
WI	Rep. Thomas E. Petri (R-06)	✓	✓			
WI	Rep. David R. Obey (D-07)				✓	✓
WI	Rep. Mark Green (R-08)	✓	✓	✓		
WI	Rep. F. James Sensenbrenner Jr. (R-09)			✓		
WV	Sen. Robert C. Byrd (D)					✓
WV	Sen. John Rockefeller (D)	✓	✓		✓	✓
WV	Rep. Alan B. Mollohan (D-01)				✓	✓
WV	Rep. Shelley Moore Capito (R-02)		✓			
WV	Rep. Nick J. Rahall II (D-03)	✓			✓	✓
WY	Sen. Craig Thomas (R)		✓			
WY	Sen. Michael B. Enzi (R)					
WY	Rep. Barbara Cubin (R-01)		✓			